Deregulation of PAX2 expression in renal cell tumours: Mechanisms and potential use in differential diagnosis

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 8, 2013, Pages 1048-1058

  Patrício, Patrícia ^a   Ramalho Carvalho, João ^a   Costa Pinheiro, Pedro ^a   Almeida, Mafalda ^a   Barros Silva, João Diogo ^a   Vieira, Joana ^a   Dias, Paula Cristina ^a   Lobo, Francisco ^a   Oliveira, Jorge ^a   Teixeira, Manuel R ^a,b   Henrique, Rui ^a,b   Jeronimo, Carmen ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Chromosome 10 monosomy; Differential diagnosis; PAX2; Promoter methylation; Renal cell tumours

Indexed keywords

MESSENGER RNA; PAX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX2;

ADULT; AGED; ARTICLE; CELL NUCLEUS; CHROMOSOME 10; CHROMOSOME 10 MONOSOMY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOCYTOMA; PATHOLOGY; PAX2; PROMOTER METHYLATION; PROMOTER REGION; RENAL CELL TUMOURS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY;

CHROMOSOME 10 MONOSOMY; DIFFERENTIAL DIAGNOSIS; PAX2; PROMOTER METHYLATION; RENAL CELL TUMOURS;

ADENOMA, OXYPHILIC; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL NUCLEUS; CHROMOSOMES, HUMAN, PAIR 10; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PAX2 TRANSCRIPTION FACTOR; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84888205093     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12090     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008: cancer incidence and mortality worldwide. Lyon: IARCPress; 2010. http://globocan.iarc.fr/map.asp?selection=9200&title=Kidney&sex= 0&type=0&statistic=2&map=5&window=1&size=1&colou r=1&scale=0&submit=%A0Execute%A0.
2. Baldewijns MM, van Vlodrop IJ, Schouten LJ, et al. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 2008; 1785: 133-55.
3. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARCPress; 2004.
4. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997; 183: 131-3.
5. Thoenes W, Storkel S, Rumpelt HJ, et al. Chromophobe cell renal carcinoma and its variants-a report on 32 cases. J Pathol. 1988; 155: 277-87.
6. Wang Q, Fang WH, Krupinski J, et al. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med. 2008; 12: 2281-94.
7. Sanyanusin P, Norrish JH, Ward TA, et al. Genomic structure of the human PAX2 gene. Genomics. 1996; 35: 258-61.
8. Ward TA, Nebel A, Reeve AE, et al. Alternative messenger RNA forms and open reading frames within an additional conserved region of the human PAX-2 gene. Cell Growth Differ. 1994; 5: 1015-21.
9. Torban E, Eccles MR, Favor J, et al. PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol. 2000; 157: 833-42.
10. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2002; 18: 41-7.
11. Dressler GR, Woolf AS. Pax2 in development and renal disease. Int J Dev Biol. 1999; 43: 463-8.
12. Cai Q, Dmitrieva NI, Ferraris JD, et al. Pax2 expression occurs in renal medullary epithelial cells in vivo and in cell culture, is osmoregulated, and promotes osmotic tolerance. Proc Natl Acad Sci USA. 2005; 102: 503-8.
13. Metsuyanim S, Pode-Shakked N, Schmidt-Ott KM, et al. Accumulation of malignant renal stem cells is associated with epigenetic changes in normal renal progenitor genes. Stem Cells. 2008; 26: 1808-17.
14. Wu H, Chen Y, Liang J, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature. 2005; 438: 981-7.
15. Schafer BW. Emerging roles for PAX transcription factors in cancer biology. Gen Physiol Biophys. 1998; 17: 211-24.
16. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 2006; 6: 52-62.
17. Gupta R, Balzer B, Picken M, et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol. 2009; 33: 241-7.
18. Brunelli M, Eble JN, Zhang S, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005; 18: 161-9.
19. Memeo L, Jhang J, Assaad AM, et al. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol. 2007; 127: 225-9.
20. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-63.
21. Edge SB, Byrd DR, Compton CC, et al. Chapter 43 - Kidney. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010: p. 479-89.
22. Pearson H, Stirling D. DNA extraction from tissue. Methods Mol Biol. 2003; 226: 33-4.
23. Mazal PR, Stichenwirth M, Koller A, et al. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol. 2005; 18: 535-40.
24. Costa VL, Henrique R, Danielsen SA, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010; 16: 5842-51.
25. Barros-Silva JD, Ribeiro FR, Rodrigues A, et al. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosom Cancer. 2011; 50: 662-71.
26. Ryan G, Steele-Perkins V, Morris JF, et al. Repression of Pax-2 by WT1 during normal kidney development. Development. 1995; 121: 867-75.
27. Gnarra JR, Dressler GR. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res. 1995; 55: 4092-8.
28. Shen SS, Truong LD, Scarpelli M, et al. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? Arch Pathol Lab Med. 2012; 136: 410-7.
29. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011; 135: 92-109.
30. Bodmer D, van den Hurk W, van Groningen JJ, et al. Understanding familial and non-familial renal cell cancer. Hum Mol Genet. 2002; 11: 2489-98.
31. Lopez-Beltran A, Carrasco JC, Cheng L, et al. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol. 2009; 16: 432-43.
32. Luu VD, Boysen G, Struckmann K, et al. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res. 2009; 15: 3297-304.